MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”), one of the world's leading professional services firms, today announced financial results for the fourth quarter and year ended December 31, 2025. In 2025, WSP delivered net revenues and adjusted EBITDA at or exceeding the high end of Management's revised outlook ranges(1). 2025 also marked historical record level achievements in several other metrics, including backlog at $17 billion, free cash flow(2) at $ ...

ORLANDO, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today provided an update on the status of its pending acquisition by Alcon Research, LLC (“Alcon”). The Company and Alcon continue to cooperate with the U.S. Federal Trade Commission (the “FTC”) staff in connection with its Request for Additional Information and Documentary Material (the “Seco ...

HOUSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- APA Corporation (Nasdaq: APA) today announced fourth-quarter and full-year 2025 results. Results can be found on the company’s website by visiting www.apacorp.com or investor.apacorp.com. APA will host a conference call on Feb. 26 at 10 a.m. Central time via the webcast link available on the company website to discuss the results. Following the conference call, a replay will be available for one year on the “Investors” page of the company’s website. About APA APA C ...

THORNTON, Colo., Feb. 25, 2026 (GLOBE NEWSWIRE) --  Ascent Solar Technologies (“Ascent” or the “Company”) (Nasdaq: ASTI), the leading U.S. innovator in the design and manufacturing of featherweight, flexible thin-film photovoltaic (PV) solutions, today announced that its previously delivered solar blankets have been successfully integrated into NOVI’s N-1 ATLAS spacecraft, scheduled to fly on the upcoming SpaceX Falcon 9 Transporter-16 launch next month. NOVI's spring mission will demonstrate GENIE™ (Geospa ...

Core Insights - NVIDIA reported record revenue of $68.1 billion for Q4 FY26, representing a 20% increase from Q3 and a 73% increase year-over-year [1][9] - For the full fiscal year 2026, NVIDIA achieved revenue of $215.9 billion, up 65% from the previous year [1][7] - The company emphasized the exponential growth in computing demand, particularly in AI, with significant enterprise adoption of AI technologies [3] Financial Performance - Q4 FY26 GAAP gross margin was 75.0%, while non-GAAP gross margin was 75.2%, both showing improvements from the previous quarter [1][6] - GAAP earnings per diluted share for Q4 FY26 were $1.76, up 35% quarter-over-quarter and up 98% year-over-year [2][6] - For fiscal 2026, GAAP earnings per diluted share were $4.90, a 67% increase from the previous year [2][7] Shareholder Returns - NVIDIA returned $41.1 billion to shareholders in FY26 through share repurchases and cash dividends [3] - The next quarterly cash dividend of $0.01 per share is scheduled for April 1, 2026 [4] Business Segments - Data Center revenue reached a record $62.3 billion in Q4 FY26, up 22% from Q3 and up 75% year-over-year [9] - Gaming revenue for Q4 FY26 was $3.7 billion, reflecting a 47% increase year-over-year but a 13% decrease from the previous quarter [14] - Automotive revenue for Q4 FY26 was $604 million, up 2% from Q3 and up 6% year-over-year [14] Strategic Developments - NVIDIA announced the launch of the Vera Rubin platform, which aims to significantly reduce inference costs in AI applications [14] - The company expanded partnerships with major cloud providers and industrial leaders to enhance AI capabilities and infrastructure [14] - NVIDIA's collaboration with Meta includes large-scale deployment of NVIDIA CPUs and GPUs, indicating a strong focus on AI infrastructure [14]

FREEHOLD, NJ, Feb. 25, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE:UMH) (TASE:UMH) reported Total Income of $261.8 million for the year ended December 31, 2025 as compared to $240.6 million for the year ended December 31, 2024, representing an increase of 9%. Total Income for the quarter ended December 31, 2025 was $67.0 million as compared to $61.9 million for the quarter ended December 31, 2024, representing an increase of 8%. Net Income Attributable to Common Shareholders amounted to $6.0 million ...

Group 1 - Freddie Mac released its Monthly Volume Summary for January 2026, detailing mortgage-related portfolios, securities issuance, risk management, delinquencies, debt activities, and other investments [1] - The company aims to enhance liquidity, stability, and affordability in the housing market across various economic cycles [2] - Since its inception in 1970, Freddie Mac has assisted tens of millions of families in buying, renting, or maintaining their homes [2]

Core Insights - The Pennant Group, Inc. reported strong financial results for the year 2025, with significant increases in revenue, net income, and adjusted earnings per share, indicating robust growth in its home health, hospice, and senior living services [1][2][4]. Financial Performance - Total revenue for 2025 was $947.7 million, a 36.3% increase from the previous year, with fourth-quarter revenue reaching $289.3 million, up 53.2% year-over-year [2][22]. - Net income for the full year was $29.6 million, a 31.1% increase, while fourth-quarter net income was $8.6 million, up 50.0% compared to the prior year quarter [2][3]. - Adjusted net income for 2025 was $41.6 million, reflecting a 38.9% increase, with fourth-quarter adjusted net income at $12.2 million, up 43.1% year-over-year [2][32]. Segment Performance - Home Health and Hospice Services segment revenue for 2025 was $732.7 million, a 41.0% increase, with fourth-quarter revenue at $233.3 million, up 64.3% [2][22]. - Senior Living Services segment revenue for 2025 was $215.0 million, a 22.3% increase, with fourth-quarter revenue at $56.1 million, up 19.6% [2][27]. Operational Metrics - Total home health admissions for 2025 were 86,076, a 44.1% increase, with fourth-quarter admissions at 28,941, up 81.3% [2][24]. - Hospice average daily census for 2025 was 4,204, a 28.6% increase, with fourth-quarter census at 5,060, up 46.9% [2][27]. - Senior living average occupancy for the fourth quarter was 80.6%, an increase of 200 basis points year-over-year, with average monthly revenue per occupied room at $5,238, up 5.6% [2][27]. Guidance for 2026 - The company anticipates total revenue for 2026 to be between $1,133.6 million and $1,171.8 million, with adjusted earnings per diluted share expected to be between $1.26 and $1.36 [5][6]. - Adjusted EBITDA for 2026 is projected to be between $88.5 million and $94.1 million [5][6]. Management Commentary - The CEO highlighted 2025 as a year of record-breaking performance and strategic growth, emphasizing the importance of operational excellence and successful integration of new operations [4][6]. - The COO noted the focus on maintaining momentum and delivering strong results across all key growth metrics, indicating confidence in continued success in 2026 [4][6].

Core Viewpoint - Purple Biotech Ltd. is changing the ratio of its American Depositary Shares (ADSs) to ordinary shares to regain compliance with Nasdaq's minimum bid price requirement, effective March 2, 2026 [1][2]. Group 1: ADS Ratio Change - The ADS Ratio will change from 1 ADS representing 200 ordinary shares to 1 ADS representing 2,000 ordinary shares, effectively a one-for-ten reverse ADS split [1][2]. - Registered holders of certificated ADSs must surrender their ADSs for cancellation to receive new ADSs, while holders of uncertificated ADSs will have their ADSs automatically exchanged [2]. - The new CUSIP number assigned due to the ADS Ratio Change is 74638P307, and the ADSs will continue to trade under the symbol "PPBT" on Nasdaq [2]. Group 2: Impact on Trading - The ADS trading price is expected to increase proportionally as a result of the ADS Ratio Change, enhancing its suitability for trading on Nasdaq [4]. - There is no assurance that the ADS trading price post-change will be equal to or greater than ten times the price before the change [4]. Group 3: Company Overview - Purple Biotech is a clinical-stage oncology company focused on developing therapies to overcome tumor immune evasion and drug resistance [5]. - The lead program, CAPTN-3, involves capped tri-specific antibodies targeting tumors while engaging T cells and NK cells, with candidates IM1240 and IM1305 in various stages of development [5]. - The pipeline includes clinical-stage assets like CM24 and NT219, targeting specific cancer types with promising outcomes in clinical studies [5].

Core Insights - Crescent Capital BDC, Inc. reported a net investment income of $1.81 per share and a net income of $0.93 per share for the year ended December 31, 2025, with a quarterly net investment income of $0.45 and net income of $0.23 for the quarter ended December 31, 2025 [1][7][9] - The company declared a regular cash dividend of $0.42 per share for the first quarter of 2026, payable on April 15, 2026 [1] Financial Highlights - As of December 31, 2025, total investments at fair value were $1,569.4 million, a decrease from $1,598.9 million as of December 31, 2024 [2][3] - Total assets were reported at $1,622.1 million, down from $1,656.3 million a year earlier [2] - Net asset value (NAV) per share was $19.10, compared to $19.98 as of December 31, 2024 [2][17] - Investment income for the year decreased to $167.3 million from $197.4 million in 2024, primarily due to lower interest income [7][8] - Total expenses for the year were $100.4 million, down from $108.4 million in 2024 [8] Portfolio & Investment Activity - The company invested $306.9 million across 25 new portfolio companies and 41 existing portfolio companies during the year ended December 31, 2025 [5] - For the fourth quarter of 2025, investments totaled $70.8 million across five new portfolio companies [6] - The portfolio consisted of 184 companies as of December 31, 2025, with a significant portion in unitranche first lien investments, accounting for 66.7% of the total fair value [3][4] Liquidity and Capital Resources - As of December 31, 2025, the company had $31.5 million in cash and cash equivalents, along with $242.0 million of undrawn capacity on its credit facilities [11] - The weighted average cost of debt was reported at 5.83%, with a debt to equity ratio of 1.25x [11]